AstraZeneca India got CDSCO approval for Durvalumab in advanced endometrial cancer treatment Durvalumab combined with carboplatin and paclitaxel is for first-line systemic therapy in dMMR cancer Approval covers Durvalumab solution for infusion 120 mg/2.4 mL and 500 mg/10 mL (Imfinzi) in India
